Handelsbanken Fonder Ab Viking Therapeutics, Inc. Transaction History
Handelsbanken Fonder Ab
- $23 Billion
- Q2 2024
A detailed history of Handelsbanken Fonder Ab transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 21,900 shares of VKTX stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
21,900
Previous 28,300
22.61%
Holding current value
$1.41 Million
Previous $2.32 Million
49.98%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VKTX
# of Institutions
442Shares Held
63.3MCall Options Held
6.23MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$651 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$388 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$330 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$145 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$120 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.94B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...